| Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). | |
| | |
MedLine Citation:
|
PMID: 17151487 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. METHODS: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (+/-1) following intravitreal injection of 1.5 mg of bevacizumab. Main outcome measures include changes in total area of fluorescein leakage from active NV and BCVA. RESULTS: Fifteen consecutive patients (men, 9 [60%]; women, 6 [40%]) were included and all completed the 12-week follow-up period of the study. The mean +/- SD age of participants was 60.08 +/- 7.75 years (median, 59.5; range, 49-73 years). At baseline, mean +/- standard error of the mean (SEM) NV leakage area was 27.79 +/- 6.29 mm2. The mean +/- SEM area of active leaking NV decreased significantly to 5.43 +/- 2.18 mm2 and 5.50 +/- 1.24 mm2 (P < 0.05, Tukey multiple comparisons post-test) at 1 and 12 weeks postinjection, respectively; at week 6 no leakage was observed. The mean +/- SEM logMAR (Snellen equivalent) BCVA improved significantly from 0.90 (20/160) +/- 0.11 at baseline to 0.76 (20/125(+2)) +/- 0.12, 0.77 (20/125(+2)) +/- 0.11, and 0.77 (20/125(+2)) +/- 0.12 at weeks 1, 6, and 12, respectively (P < 0.05, Tukey multiple comparisons post-test). No major adverse events were observed. CONCLUSIONS: Intravitreal injection of bevacizumab achieved short-term reduction of fluorescein leakage from persistent active NV without loss of vision in patients with diabetic retinopathy. Further studies to investigate the role of anti-VEGF therapy with bevacizumab for the management of diabetic retinopathy refractory to laser treatment are warranted. |
| | |
Authors:
|
Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Léssia P Cintra; Ingrid U Scott |
Related Documents
:
|
6393437 - Peripheral vascular disease in japanese diabetics: screening by the doppler ultrasonic ... 16996597 - The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabe... 9076207 - Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-... 7188047 - Long-term improvement of metabolic control with the insulin pump does not reverse diabe... 14722397 - Perinephric abscess from insulin syringe reuse. 17547837 - Prevention of type 2 diabetes: an update. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Retina (Philadelphia, Pa.) Volume: 26 ISSN: 0275-004X ISO Abbreviation: Retina (Philadelphia, Pa.) Publication Date: 2006 Nov-Dec |
Date Detail:
|
Created Date: 2006-12-07 Completed Date: 2007-01-04 Revised Date: 2007-05-02 |
Medline Journal Info:
|
Nlm Unique ID: 8309919 Medline TA: Retina Country: United States |
Other Details:
|
Languages: eng Pagination: 1006-13 Citation Subset: IM |
Affiliation:
|
Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil. rjorge@fmrp.usp.br |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiogenesis Inhibitors / therapeutic use* Antibodies, Monoclonal / therapeutic use* Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 2 / complications Diabetic Retinopathy / diagnosis, drug therapy*, physiopathology Female Fluorescein Angiography Follow-Up Studies Humans Injections Male Middle Aged Retinal Neovascularization / diagnosis, drug therapy*, physiopathology Treatment Outcome Vascular Endothelial Growth Factor A / antagonists & inhibitors, immunology Visual Acuity / physiology Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Next Document: Anterior chamber collapse following vitreoretinal surgery with gas tamponade in aphakic eyes: incide...